ANVS

Annovis Bio Inc

Add to Watchlist

Advanced Chart

2.770

-0.05(-1.773%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.820

Open

2.820

VWAP

2.77

Vol

244.87K

Mkt Cap

53.98M

Low

2.700

Amount

678.27K

EV/EBITDA(TTM)

Total Shares

11.17M

32.71M

EV/OCF(TTM)

P/S(TTM)

Annovis Bio, Inc. is a late-stage clinical drug platform company addressing neurodegeneration such as Alzheimer’s disease (AD), and Parkinson’s disease (PD). The Company is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury and/or stroke. ANVS405 is the same compound as Buntanetap, given in cases of acute head and brain trauma. ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 is observed to improve memory and learning in very old rats by lowering the number of errors from over six to three.

Get winning stock picks in minutes

3 Analyst Rating

345.13% Upside

Wall Street analysts forecast ANVS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANVS is 12.33 USD with a low forecast of 8.00 USD and a high forecast of 17.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

345.13% Upside

Current: 2.770

Low

8.00

Averages

12.33

High

17.00

345.13% Upside

Current: 2.770

Low

8.00

Averages

12.33

High

17.00

H.C. Wainwright

Buy

downgrade

$30 -> $12

2025-06-09

Reason

H.C. Wainwright

Price Target

$30 -> $12

2025-06-09

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Annovis Bio to $12 from $30 and keeps a Buy rating on the shares. The firm cites the impact of the most recent equity financing in February of this year, future potential equity issuances and the exercise of warrants for the target cut.

Canaccord

Sumant Kulkarni

Buy

downgrade

$26 -> $17

2025-05-15

Reason

Canaccord

Sumant Kulkarni

Price Target

$26 -> $17

2025-05-15

downgrade

Buy

Reason

Canaccord analyst Sumant Kulkarni lowered the firm's price target on Annovis Bio to $17 from $26 and keeps a Buy rating on the shares. The firm noted the released Q1 results which showed the company initiated its pivotal Phase 3 clinical trial for buntanetap for early Alzheimer's disease (AD). Previously the company had said earlier that it had reached alignment with the FDA on a pivotal trial with a 6-month endpoint focused on symptomatic benefit and an 18-month endpoint to address disease progression in early AD.

D. Boral Capital

Jason Kolbert

Strong Buy

Hold

Downgrades

n/a

2025-02-10

Reason

D. Boral Capital

Jason Kolbert

Price Target

n/a

2025-02-10

Downgrades

Strong Buy

Hold

Reason

D. Boral Capital downgraded Annovis Bio to Hold from Buy without a price target after the company announced the pricing of an underwritten public offering of 5.25M shares. While the form anticipated a capital raise, the structure of the deal left it "disappointed." The company's ability to fully realize the second phase of this financing now depends on the stock reaching $5, the analyst tells investors in a research note. Boral says that instead of eliminating the financing overhang, the capital raise structure prolongs it, weighing on the stock and altering its investment thesis.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$21

2024-11-11

Reason

D. Boral Capital

Jason Kolbert

Price Target

$21

2024-11-11

Maintains

Strong Buy

Reason

Annovis Bio announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis' clinical trials.

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

$30

2024-11-11

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

$30

2024-11-11

Reiterates

Strong Buy

Reason

Maxim Group

Jason McCarthy

Hold

Strong Buy

Upgrades

$25

2024-10-25

Reason

Maxim Group

Jason McCarthy

Price Target

$25

2024-10-25

Upgrades

Hold

Strong Buy

Reason

Maxim upgraded Annovis Bio to Buy from Hold with a $25 price target.

See All Ratings

Get winning stock picks in minutes

Valuation Metrics

The current forward P/E ratio for Annovis Bio Inc (ANVS.N) is -1.79, compared to its 5-year average forward P/E of -6.96. For a more detailed relative valuation and DCF analysis to assess Annovis Bio Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.96

Current PE

-1.79

Overvalued PE

1.64

Undervalued PE

-15.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-0.85

Current EV/EBITDA

-0.66

Overvalued EV/EBITDA

0.37

Undervalued EV/EBITDA

-2.06

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00